Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Saxagliptin in T2DM Poorly Controlled with Metformin
NCT03714594Phase 2Completed
- Sponsor
- University of Pisa
- Start
- Jul 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin + Dapagliflozin, Saxagliptin + Placebo and Dapagliflozin + Placebo (3 arms). Primary endpoint: Glucose Metabolism at 4 weeks. Started Jul 2018; status: completed.
02
Drugs
dapagliflozinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03714594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714594.